1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

FDA’s FY 2023 Proposed Budget Asks For Millions To Curb Device Shortages, Bolster Cybersecurity, And More

 
• By Shawn M. Schmitt

The US FDA’s medical devices program would get a funding boost of more than 9% over the current fiscal year if the agency’s latest budget request is granted as-is by Congress.

Pink piggy bank drowning in ocean of copper pennies.
• Source: Alamy

The US Food and Drug Administration’s budget request for fiscal year 2023, released on 28 March, asks Congress for an additional $21.6m to curb medical device shortages and beef up the country’s supply chain for devices.

“This funding will provide resources that will enable establishment of a permanent program for US supply chain resilience for medical devices for the first time,” the FDA says in its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Pathogen Sharing System Part Of Global Pandemic Agreement

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.

FDA Halts Acceptance Of Chinese Lab Data Due To Accuracy Issues

 
• By Elizabeth Orr

The FDA has stopped accepting data from two Chinese labs due to accuracy issues. Mid-Link and SDWH have been flagged for potentially falsified results and other misconduct. This decision, which follows months of discussions and warnings, emphasizes the FDA's commitment to ensuring data integrity in medical device submissions.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.